Authored by Karl Simpson
Anti-PD1 Antibody combined with TIM-3 and LAG-3 antagonists
Cancer Immunotherapy is an area that is gaining increasing levels of interest across the cancer therapeutics markets and in the life sciences market in general. This year, new data was announced at the ASCO meeting which showed some promise for the various PD-1 programmes being developed by companies like BMS and Merck and the PDL-1 programme by Roche.
Nestled down in San Diego, California is a small biotech developing an immunotherapy portfolio. This company is AnaptysBio, a privately held company with some marque venture capital backers in Avalon Ventures (who recently announced a deal with GSK), Alloy Ventures and also Novo A/S (the venture arm of Novo Nordisk).
AnaptysBio is led by CEO – Hamza Suria, an alliances and BD executive formerly of Maxygen. While the science effort is led by CSO – David King, an expert in antibody engineering and antibody therapeutics from the UK who while at Celltech (now part of UCB), led the invention of Cimzia®. The company is focused on the use of somatic hypermutation (SHM) for antibody discovery and is developing its own pipeline of products in cancer immunotherapy, inflammation, fibrosis and ADCs.
AnaptysBio has stated it is expanding its proprietary immunotherapy antibody portfolio to include multiple new combination therapies. Its proprietary platform, SHM-XEL™, was used to develop an anti-PD-1 antibody, called ANB011. The company is also developing novel antibodies against other checkpoint receptors, including TIM-3 and LAG-3 which could be used in combination with the ANB011 asset.